Table 1. Baseline patient characteristics.
| Arm A: 840/420 mg pertuzumab, n=15 | Arm B: 840 mg q3w pertuzumab, n=15 | |
|---|---|---|
|
Age, years | ||
| Median (min–max) | 67 (29–76) | 59 (27–72) |
| <65, n (%) |
6 (40.0) |
10 (66.7) |
|
Sex,
n
(%) | ||
| Male |
14 (93.3) |
10 (66.7) |
|
Ethnicity,
n
(%) | ||
| Hispanic or Latino | 2 (13.3) | 1 (6.7) |
| Not Hispanic or Latino |
13 (86.7) |
14 (93.3) |
|
Race,
n
(%) | ||
| Asian | 9 (60.0) | 8 (53.3) |
| White |
6 (40.0) |
7 (46.7) |
|
Weight, kg | ||
| Median (min–max) |
67.0 (47.0–83.0) |
66.8 (52.0–89.0) |
|
Extent of disease on entry,
n
(%) | ||
| Metastatic | 13 (86.7) | 12 (80.0) |
| Unresectable, locally advanced |
2 (13.3) |
3 (20.0) |
|
Primary site,
n
(%) | ||
| Stomach | 12 (80.0) | 13 (86.7) |
| Gastro–oesophageal junction |
3 (20.0) |
2 (13.3) |
|
Measurability,
n
(%) | ||
| Measurable disease | 12 (80.0) | 13 (86.7) |
| Non-measurable evaluable disease only |
3 (20.0) |
2 (13.3) |
|
Histologic subtypes,
n
(%) | ||
| Intestinal | 6 (40.0) | 5 (33.3) |
| Diffuse | 1 (6.7) | 3 (20.0) |
| Not known | 8 (53.3) | 7 (46.7) |